The use of multiparameter flow cytometry to assess tumor cell heterogeneity and grade prostate cancer

No abstract is available for this paper.

• Publication year

  1984

• Venue

  The Prostate

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/pros.2990050104PMID 6694917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multistation multiparameter flow cytometry: a critical review and rationale.

  1983cited by this paper
• Limitations of DNA histogram analysis by flow cytometry as a method of predicting chemosensitivity in a rat renal cancer model.

  1983cited by this paper
• Tumor cell heterogeneity : origins and implications

  1982cited by this paper
• A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness.

  1982cited by this paper
• Prediction of lymphatic metastases by Gleason histologic grading in prostatic cancer.

  1982cited by this paper
• Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system.

  1982cited by this paper
• Aid to accurate clinical staging-histopathologic grading in prostatic cancer.

  1982cited by this paper
• Relationship between grade and stage of adenocarcinoma of the prostate and regional pelvic lymph node metastases.

  1982cited by this paper
• Light scatter analysis and sorting of cells activated in mixed leukocyte culture.

  1982cited by this paper
• Staging errors in clinically localized prostatic cancer.

  1982cited by this paper
• Flow cytometry and cell sorting.

  1980cited by this paper
• Light scattering properties of murine hemopoietic cells.

  1980cited by this paper
• Histologic grading of primary prostatic cancer: a new approach to an old problem.

  1980cited by this paper
• Experience with Gleason's histopathologic grading in prostatic cancer.

  1980cited by this paper
• Identification of CFU-s by Scatter Measurements on a Light Activated Cell Sorter

  1979cited by this paper
• Nucleoli visualized by silver staining combined with a new RNA-specific fluorochrome.

  1979cited by this paper
• A report of the workshops on the current status of the histologic grading of prostate cancer

  1979cited by this paper
• Immunofluorescence and Related Staining Techniques

  1979cited by this paper
• Chromomycin A3 as a fluorescent probe for flow cytometry of human gynecologic samples.

  1977cited by this paper
• Pulse-height light-scatter distributions using flow-systems instrumentation.

  1976cited by this paper
• Grading of prostatic carcinoma.

  1975cited by this paper
• ANALYSIS OF CELL POPULATIONS WITH A FLUORESCENCE‐ACTIVATED CELL SORTER *

  1975cited by this paper
• Cell classification by laser light scattering: identification and separation of unstained leukocytes.

  1975cited by this paper
• Differential light scattering from spherical mammalian cells.

  1974cited by this paper
• The small angle light scattering of biological cells. Theoretical considerations.

  1970cited by this paper
• Classification of prostatic carcinomas.

  1966cited by this paper
• PROSTATE CANCER IN THE RAT.

  1963cited by this paper

• Preface of the special issue in memoriam and celebration of Donald S. Coffey from special issue senior guest editor.

  2018cites this paper
• Histomorphometry of digital pathology: Case study in prostate cancer

  2014cites this paper
• Nuclear Morphometry, Epigenetic Changes, and Clinical Relevance in Prostate Cancer

  2013cites this paper
• Nuclear morphometry, nucleomics and prostate cancer progression.

  2012cites this paper
• Drug-related hepatotoxicity and hepatic failure following combined androgen blockade

  2008cites this paper
• DNA Flow Cytometry and Histopathological Grading of Paraffin-embedded Prostate Biopsy Specimens in a Survival Study 1

  2006cites this paper
• Management of Metastatic Prostate Cancer

  2003cites this paper
• Building the Road to Defeat Prostate Cancer

  2001cites this paper
• Building the Road to Defeat Prostate Cancer: A Dedication to Donald S. Coffey

  2000cites this paper
• Controversies in the management of advanced prostate cancer

  1999cites this paper
• Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.

  1998cites this paper
• Treatment options for early prostate cancer.

  1998cites this paper
• Worldwide activity and safety of bicalutamide: a summary review.

  1996cites this paper
• Indications for Antiandrogen Treatment in Prostate Cancer

  1996cites this paper
• Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

  1996cites this paper
• A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.

  1996cites this paper
• A glimpse at the future of some endocrine aspects of prostate cancer

  1996cites this paper
• Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.

  1995cites this paper
• A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

  1995cites this paper
• Chapter 7 – Androgen Receptors in Human Prostate Cancer

  1994cites this paper
• Image analysis of androgen receptor immunostaining in metastatic prostate cancer heterogeneity as a predictor of response to hormonal therapy

  1993cites this paper
• Nuclear roundness factor and local failure from definitive radiation therapy for prostatic carcinoma.

  1992cites this paper
• Flow cytometry in carcinoma of the prostate.

  1990cites this paper
• In vitro studies of human prostatic epithelial cells: attempts to identify distinguishing features of malignant cells.

  1989cites this paper
• Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.

  1988cites this paper
• Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model.

  1987cites this paper
• Carcinoma of the prostate. Hormonal therapy

  1987cites this paper
• DNA flow cytometry and histopathological grading of paraffin-embedded prostate biopsy specimens in a survival study.

  1987cites this paper
• Clinical Trials in Prostatic Cancer: Methodology and Controversies

  1987cites this paper
• Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers

  1987cites this paper
• The epithelial origin of a stromal cell population in adenocarcinoma of the rat prostate.

  1987cites this paper
• Correlation of prognosis to nuclear roundness and to flow cytometric light scatter.

  1987cites this paper
• Characterization of the heterogeneity of R3327 rat prostatic tumors derived from single‐cell clones

  1986cites this paper
• Distinctive protein pattern in two-dimensional electrophoretograms of cancerous prostatic tissues.

  1986cites this paper
• Flow cytometry in urologic oncology.

  1986cites this paper
• The application of flow cytometry to the assessment of tumor cell heterogeneity and the grading of human prostatic cancer: preliminary results.

  1986cites this paper
• Cellular Heterogeneity of Human Tumors

  1985cites this paper
• Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the dunning R-3327 rat prostatic adenocarcinoma system as a model.

  1984cites this paper